Reference studies clinical trials
Interventional studies
Myeloproliferative neoplasms and acute myeloid leukemia
New insights into the use of decitabine versus hydroxyurea in the treatment of advanced proliferative chronic myelomonocytic leukemia.
01.12.2022
● Prof. Dr. med. habil. Uwe Platzbecker
show more
Interventional studies
Type 2 diabetes
New insights into the impact of the direct factor Xa inhibitor rivaroxaban on endothelial function in patients with type 2 diabetes and high cardiovascular risk.
12.2021
● Prof. Dr. med. habil. Stefan Bornstein
show more
Non-interventional studies
Pulmonary hypertension
New insights into the impact of smoking history, DLCO, chest CT findings, and left heart disease risk factors on the classification of unexplained precapillary pulmonary hypertension (IPAH).
10.2022
● Prof. Dr. med. habil. David Pittrow
show more
Interventional studies
Superficial vein thrombosis–treatment and complications
New Evidence on the Role of the Oral Factor Xa Inhibitor Rivaroxaban in the Treatment of Patients with Symptomatic Superficial Venous Thrombosis
03.2017
● Prof. Dr. med. habil. Jan Beyer-Westendorf
show more
Interventional studies
Diabetes polyneuropathy
New insights into the use of Sudoscan technology compared with quantitative sudomotor axon reflex testing (QSART) in the detection of diabetic polyneuropathy (DPN).
26.09.2018
● Prof. Dr. med. habil. Tjalf Ziemssen
show more
Interventional studies
VEGF and Type 2 diabetes
New insights into intra-individual variability and circadian rhythm of vascular endothelial growth factors (VEGF) in patients with type 2 diabetes.
09.10.2017
● Prof. Dr. med. habil. Katrin Engelmann
show more
Non-interventional studies
Idiopathic pulmonary fibrosis
New insights into the impact of antifibrotic therapy on survival and the course of disease in patients with idiopathic pulmonary fibrosis (IPF)
08/13/2020
● Prof. Dr. med. habil. Dirk Koschel
show more
Hit enter to search or ESC to close
You are using an outdated browser. The website may not be displayed correctly. Close
